Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Policy / Regulatory

NMPA and Local Governments Streamline Drug Approval Processes in China

Fineline Cube Nov 26, 2024

The National Medical Products Administration (NMPA) has released a notification regarding the pilot work for...

Company Deals

Adcendo ApS Secures Oversubscribed USD135 Million Series B Financing to Advance ADC Pipeline

Fineline Cube Nov 26, 2024

Danish antibody drug conjugate (ADC) specialist, Adcendo ApS, has announced the completion of an oversubscribed...

Company Medical Device

Abbott Laboratories Expands Structural Heart Portfolio with TAVI Balloon-Expandable System

Fineline Cube Nov 26, 2024

US-based Abbott Laboratories (NYSE: ABT) has announced the successful application of its transcatheter aortic valve...

Company Drug

Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH

Fineline Cube Nov 26, 2024

US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced positive interim analysis results...

Company Deals

Boston Scientific Corporation to Acquire Intera Oncology Inc., Expanding Cancer Treatment Portfolio

Fineline Cube Nov 26, 2024

US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has announced a definitive acquisition agreement...

Company Drug

Nasal-Phyto Pharmaceutical Receives FDA Clearance for First-Ever Olfactory Drug-Device Combo

Fineline Cube Nov 26, 2024

China-based Nasal-Phyto Pharmaceutical Technology Group Co., Ltd has announced receiving clinical clearance from the US...

Company Drug

GSK’s Blenrep BLA for Multiple Myeloma Treatments Accepted by FDA for Review

Fineline Cube Nov 26, 2024

UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that the US Food and Drug...

Company Drug

Insilico Medicine Gets FDA Approval for Clinical Study of ENPP1 Inhibitor ISM5939

Fineline Cube Nov 26, 2024

China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received...

Company Drug

SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024

Fineline Cube Nov 26, 2024

SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has announced...

Company Drug

Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine

Fineline Cube Nov 26, 2024

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the enrollment of the...

Company Drug

Sichuan Kelun-Biotech Receives NMPA Clearance for SKB501 Clinical Trial in Solid Tumors

Fineline Cube Nov 26, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...

Company Drug

Lepu Medical Technology Gains NMPA Approval for Obesity and Diabetes Treatments MWN109 and MWN105

Fineline Cube Nov 26, 2024

China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease...

Company Deals

3SBio Inc. Secures Licensing Deal with Sunshine Lake Pharma for Clifutinib Commercialization

Fineline Cube Nov 26, 2024

China-based 3SBio Inc. (HKG: 1530) has announced a licensing deal with fellow Chinese firm Sunshine...

Company Drug

Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH

Fineline Cube Nov 26, 2024

US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced favorable interim analysis results...

Company Deals

Hubei Guangji Pharmaceutical Expands Ex-Hospital Market Presence with New Partnerships

Fineline Cube Nov 26, 2024

China-based Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) is poised to establish a strong presence...

Company Drug

GeneQuantum Healthcare’s GQ1011 (AMB302) Receives FDA Approval for Clinical Study

Fineline Cube Nov 26, 2024

China-based GeneQuantum Healthcare, a leading developer of antibody drug conjugates (ADCs), has announced that it...

Company Deals

E-nitiate Biopharmaceuticals Strikes Licensing Deal with Joincare for QY101 Inhaler Rights

Fineline Cube Nov 26, 2024

China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a joint venture between VivaVision Biotech and Betta Pharmaceuticals...

Company Deals

Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil

Fineline Cube Nov 25, 2024

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),...

Company Deals

Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million

Fineline Cube Nov 25, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan,...

Company

Danish Pharma H. Lundbeck A/S Sees Strong Q3 and Q1-Q3 2024 Financial Results

Fineline Cube Nov 25, 2024

Denmark-based pharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has revealed its financial results for the...

Posts pagination

1 … 298 299 300 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.